AUPH Aurinia Pharmaceuticals Inc

15.18
+0.34  (+2%)
Previous Close 14.84
Open 15
Price To Book 6.2
Market Cap 1,697,097,815
Shares 112,297,331
Volume 1,303,577
Short Ratio
Av. Daily Volume 1,649,739
Stock charts supplied by TradingView

NewsSee all news

  1. venBio Closes $394 Million Life Sciences Venture Capital Fund

    venBio Partners LLC today announced the closing of venBio Global Strategic Fund III ("venBio Fund III"), its third life sciences venture capital fund, exceeding its target and closing on approximately $394 million in

  2. Aurinia Announces AURORA Phase 3 Clinical Data for Voclosporin in Lupus Nephritis to be Presented at National Kidney Foundation 2020 Spring Clinical Meetings

    - Data to be shared as a late-breaking oral presentation during the live virtual NKF conference - Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical

  3. Aurinia Pharmaceuticals Establishes U.S. Commercial Operations Center in Rockville, Maryland

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that the

  4. Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis

    - Company remains on track to complete submission by the end of the second quarter 2020 - Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical

  5. Aurinia Launches Resource Kit for People Living With Lupus Nephritis and Partners With National Kidney Foundation on Awareness Initiative

    - Company recognizes World Kidney Day and National Kidney Month - Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) ("Aurinia" or the "Company") , a late-stage clinical biopharmaceutical company focused on advancing

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2/3 data due 2H 2020.
Voclosporin
Dry eye syndrome
Phase 2 interim data due 2H 2020.
Voclosporin
Focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD)
NDA rolling submission has commenced - noted March 16, 2020. To be completed 2Q 2020.
Voclosporin - AURORA
Lupus
Phase 2 trial enrollment has commenced - noted June 25, 2018.
Voclosporin - AURORA 2
Lupus

Latest News

  1. venBio Closes $394 Million Life Sciences Venture Capital Fund

    venBio Partners LLC today announced the closing of venBio Global Strategic Fund III ("venBio Fund III"), its third life sciences venture capital fund, exceeding its target and closing on approximately $394 million in

  2. Aurinia Announces AURORA Phase 3 Clinical Data for Voclosporin in Lupus Nephritis to be Presented at National Kidney Foundation 2020 Spring Clinical Meetings

    - Data to be shared as a late-breaking oral presentation during the live virtual NKF conference - Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical

  3. Aurinia Pharmaceuticals Establishes U.S. Commercial Operations Center in Rockville, Maryland

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that the

  4. Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis

    - Company remains on track to complete submission by the end of the second quarter 2020 - Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical

  5. Aurinia Launches Resource Kit for People Living With Lupus Nephritis and Partners With National Kidney Foundation on Awareness Initiative

    - Company recognizes World Kidney Day and National Kidney Month - Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) ("Aurinia" or the "Company") , a late-stage clinical biopharmaceutical company focused on advancing

  6. Aurinia Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights

    - Cash and cash equivalents totaled approximately $306 million at December 31, 2019 - - Positive AURORA Phase 3 results with voclosporin enabling an NDA submission for the treatment of lupus nephritis ("LN") by the

  7. Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results on March 5, 2020

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) (the "Company") today announced that it will release its fourth quarter and full year 2019 financial results on Thursday, March 5, 2020, after the markets close.

  8. Aurinia Appoints Max Colao as Chief Commercial Officer and Expands U.S. Commercial Leadership Team

    - Industry veteran, Max Colao, appointed Chief Commercial Officer - - Recruited four seasoned executives with expertise across critical commercial functions - - Rapidly preparing for the potential commercialization

  9. Aurinia Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare Conference

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) (the "Company") today announced that Mr. Peter Greenleaf, President and Chief Executive Officer, will present a corporate overview at the 9th Annual SVB Leerink Global

  10. Aurinia Closes US$191.7 Million Public Offering of Common Shares and Full Exercise of Underwriters' Option to Purchase Additional Common Shares

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the closing of

  11. Aurinia Prices US$166.7 Million Public Offering of Common Shares

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the pricing of

  12. Aurinia Announces Public Offering of Common Shares

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that it has

  13. Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis

    - Voclosporin achieved statistically superior Renal Response rate (p < 0.001) and comparable safety profile versus standard of care - - Statistically significant results demonstrated in all pre-specified

  14. Hepion Pharmaceuticals Announces Canadian Research Team's Academic Appointments

    University of Alberta's Faculty of Pharmacy and Pharmaceutical Sciences Appoints Hepion's Drs. Foster, Mayo, Ure and Trepanier as Adjunct Professors EDISON, NJ / ACCESSWIRE / December 3, 2019 / Hepion

  15. Aurinia to Present Preclinical Voclosporin Data at 2020 Keystone Symposia Conference

    - Voclosporin demonstrated fewer adverse effects on beta cell function as compared to tacrolimus in preclinical model of diabetes - - Data supports differentiation of voclosporin versus legacy CNIs and potential

  16. Aurinia Reports Third Quarter 2019 Financial Results and Recent Operational Highlights

    - Conference call and webcast to be hosted today at 4:30pm EDT – Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing

  17. Aurinia Announces Updates to the Board of Directors

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions,

  18. Aurinia Completes Voclosporin Drug-Drug Interaction Study Demonstrating No Clinically Significant Interaction With Mycophenolate Mofetil

    - Data support differentiation of voclosporin as a potential best-in-class CNI - Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused

  19. Aurinia Pharmaceuticals to Release Third Quarter 2019 Financial Results on November 14, 2019

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) (the "Company") today announced that it will release its third quarter 2019 financial results on Thursday, November 14, 2019, after the market closes. Aurinia's

  20. Aurinia Announces Initiation of Patient Dosing in Phase 2/3 AUDREY™ Clinical Trial for Dry Eye Syndrome

    - Voclosporin ophthalmic solution (VOS) AUDREY trial results anticipated in the second half of 2020 – Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical

  21. Aurinia Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) (the "Company") today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat at the 2019 Cantor Global

  22. Aurinia Establishes At-the-Market Facility

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) ("Aurinia" or the "Company"), a late- stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that it has

  23. Aurinia Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) (the "Company") today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will present a corporate overview at the 21st Annual H.C.